Samsung Biologics and ImmuneOncia Therapeutics have achieved successful U.S. FDA IND approval of IMC-002 under a development and manufacturing agreement. As a result, ImmuneOncia will begin Phase 1 clinical trials of the pipeline product.   IMC-002 is an immune checkpoint inhibitor antibody, which blocks CD47-SIRP- α interaction between tumor cells and macrophages. According to ImmuneOncia, IMC-002 is expected to help patients with metastatic or locally advanced solid tumors and relapsed or refr...